Drugdu.com expert's response:

Mazdutide has demonstrated significant efficacy in weight reduction, glycemic control, and comprehensive metabolic improvement, along with favorable safety and tolerability profiles. The specific therapeutic effects are as follows:

I. Weight Reduction

Phase III Clinical Trial Data: In the pivotal Phase III GLORY-1 trial, after 48 weeks of treatment, the 4mg mazdutide group achieved an average weight reduction of 11.0%, while the 6mg group reached an impressive 14.0%, significantly outperforming the placebo group (0.3%). Notably, 66.7% of patients in the 6mg group lost over 10% of their body weight, and nearly half (49.5%) lost more than 15%.

Real-World Cases: One patient using 6mg of mazdutide for 24 weeks saw their weight drop from 92kg to 78kg, with a 12cm reduction in waist circumference. Another female patient with a BMI of 32 experienced a weight reduction from 92kg to 76.8kg and a 12cm decrease in waist circumference after 48 weeks of treatment with the 6mg dose.

Special Dose Efficacy: The 9mg mazdutide regimen demonstrated a weight reduction of 15.4% (14.7kg) relative to placebo in a Chinese obese population with an average BMI of 34.3kg/m² after 24 weeks of treatment, rivaling the weight loss effects observed in some patients undergoing metabolic surgery.

II. Glycemic Control

Clinical Trial Data: Mazdutide effectively reduced glycated hemoglobin (HbA1c) levels by up to 2.15%, indicating robust glycemic control.

Indication Expansion: Another glycemic control indication for mazdutide is expected to receive approval soon, further expanding its application in diabetes management.

III. Comprehensive Metabolic Improvement

Cardiovascular Metabolic Indicators: Mazdutide significantly improved multiple cardiovascular metabolic markers. After 48 weeks, patients in the 6mg group experienced a notable reduction in waist circumference (average decrease of 10.7cm), systolic blood pressure (average decrease of 9.9mmHg), triglycerides (31.5% reduction), serum uric acid (12.9% reduction, with more pronounced effects in patients with baseline hyperuricemia), and liver enzymes (ALT levels also improved significantly).

Liver Fat Metabolism: Mazdutide had a marked effect on improving liver fat metabolism. Clinical trials showed an average reduction in liver fat content of 73.3%, with some patients achieving reductions of up to 80%.

IV. Safety and Tolerability

Adverse Reactions: The primary adverse reactions to mazdutide were mild to moderate gastrointestinal symptoms, such as nausea and diarrhea, predominantly occurring during the dose escalation phase, with a significant decline in incidence during the maintenance phase. The discontinuation rate due to adverse events was only 1.0%, comparable to that of the placebo group.

Long-Term Safety: Mazdutide has accumulated extensive long-term safety data, offering value for specific patient populations (e.g., those requiring a more gradual treatment initiation). Its dose titration scheme (2mg → 4mg → 6mg) also facilitates patient adaptation and minimizes initial discomfort.